A Phase 3 interventional study of Budesonide and Conventional Asthma Therapy in Asthma, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2012-08-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 39th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2006, is one of 51 in phase 3, and was the 28th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 107th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2006, is one of 121 in phase 3, and was the 59th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres. To investigate the safety of budesonide Turbuhaler® with a daily dose of 100 µg to 800 µg for 54 weeks treatment including the prior 6 weeks Phase III study (Study D5254C00769, NCT00504062) as compared with conventional therapy in Japanese children with bronchial asthma in need of inhaled glucocorticosteroid treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
Drug: Budesonide
Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Drug: Conventional Asthma Therapy
Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
Also known as: Pulmicort® Turbuhaler®
According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Number of Patients With Adverse Events (AEs).
AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.
Time frame: 54 weeks
Number of Patients With Abnormal Clinical Laboratory Test Values.
Analysis of haematological, clinical chemistry and urynalysis variables were performed. Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count. Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen. Urinalysis variables: protein, glucose, urobilinogen, occult.
Time frame: 54 weeks
Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator
Time frame: 54 weeks
Number of Patients With Abnormal Plasma Cortisol Values.
Cut-off value of cortisol is defined as 4 mcg/dL.
Time frame: 54 weeks
Height
Height, change from baseline calculated as (height at last visit - height at randomization)
Time frame: Baseline and 54 weeks
Weight
Weight, change from baseline calculated as (weight at last visit - weight at randomization)
Time frame: Baseline and 54 weeks
Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal
Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).
Time frame: 54 weeks
Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)
Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency
Time frame: Baseline and 54 weeks
Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)
Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization). Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.
Time frame: Baseline and 54 weeks
Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)
Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)
Time frame: Baseline and 54 weeks
Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)
Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)
Time frame: Baseline and 54 weeks
Change From Baseline in Disturbance of Daily Activities
Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization). Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).
Time frame: Baseline and 54 weeks
Change From Baseline in Disturbance of Night-time Sleep
Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization). Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).
Time frame: Baseline and 54 weeks
Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline
Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).
Time frame: 54 weeks
241 Japanese paediatric patients were enrolled into the study
| Milestone | Budesonide | Conventional Therapy |
|---|---|---|
| Started | 121 | 120 |
| Completed | 109 | 113 |
| Not completed | 12 | 7 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Non-compliance | 2 | 1 |
AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.
| Participants | Budesonide | Conventional Therapy |
|---|---|---|
| Number of Patients With Adverse Events (AEs). | 118 | 116 |
Analysis of haematological, clinical chemistry and urynalysis variables were performed. Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count. Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen. Urinalysis variables: protein, glucose, urobilinogen, occult.
| Participants | Budesonide | Conventional Therapy |
|---|---|---|
| Number of Patients With Abnormal Clinical Laboratory Test Values. | 0 | 0 |
| Participants | Budesonide | Conventional Therapy |
|---|---|---|
| Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator | 0 | 0 |
Cut-off value of cortisol is defined as 4 mcg/dL.
| Participants | Budesonide | Conventional Therapy |
|---|---|---|
| Number of Patients With Abnormal Plasma Cortisol Values. | 20 | 12 |
Height, change from baseline calculated as (height at last visit - height at randomization)
| Centimeters | Budesonide | Conventional Therapy |
|---|---|---|
| Height | 5.34 ± 1.99 | 6.35 ± 1.89 |
Weight, change from baseline calculated as (weight at last visit - weight at randomization)
| kilograms | Budesonide | Conventional Therapy |
|---|---|---|
| Weight | 3.78 ± 2.77 | 4.39 ± 3.22 |
Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).
| Percentage | Budesonide | Conventional Therapy |
|---|---|---|
| Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal | 9.54 ± 19.87 | 5.84 ± 17.81 |
Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency
| Points on a scale | Budesonide | Conventional Therapy |
|---|---|---|
| Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime) | -0.139 ± 0.334 | -0.156 ± 0.302 |
Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization). Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.
| Points on a scale | Budesonide | Conventional Therapy |
|---|---|---|
| Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime) | -0.12 ± 0.29 | -0.147 ± 0.3 |
Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)
| Puffs per day | Budesonide | Conventional Therapy |
|---|---|---|
| Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime) | -0.21 ± 0.647 | -0.242 ± 0.485 |
Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)
| Puffs per day | Budesonide | Conventional Therapy |
|---|---|---|
| Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time) | -0.07 ± 0.415 | -0.097 ± 0.368 |
Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization). Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).
| Disturbances per day | Budesonide | Conventional Therapy |
|---|---|---|
| Change From Baseline in Disturbance of Daily Activities | -0.037 ± 0.141 | -0.017 ± 0.141 |
Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization). Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).
| Disturbances per night | Budesonide | Conventional Therapy |
|---|---|---|
| Change From Baseline in Disturbance of Night-time Sleep | -0.029 ± 0.134 | -0.042 ± 0.132 |
Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).
| Percentage | Budesonide | Conventional Therapy |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline | 1.5 ± 15.59 | 2.31 ± 16.63 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Budesonide | — | 10/121 (8.3%) | 100/121 (82.6%) |
| Conventional Therapy | — | 11/120 (9.2%) | 113/120 (94.2%) |
| Event | Budesonide | Conventional Therapy |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/121 | 6/120 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 0/121 | 3/120 |
| PneumoniaInfections and infestations | 1/121 | 2/120 |
| Abdominal painGastrointestinal disorders | 0/121 | 1/120 |
| Gastroenteritis rotavirusInfections and infestations | 0/121 | 1/120 |
| HypotensionVascular disorders | 0/121 | 1/120 |
| Adenoviral conjunctivitisInfections and infestations | 1/121 | 0/120 |
| AppendicitisInfections and infestations | 1/121 | 0/120 |
| GastroenteritisInfections and infestations | 1/121 | 0/120 |
| InfluenzaInfections and infestations | 1/121 | 0/120 |
| Event | Budesonide | Conventional Therapy |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 68/121 | 60/120 |
| BronchitisInfections and infestations | 40/121 | 46/120 |
| PharyngitisInfections and infestations | 36/121 | 40/120 |
| GastroenteritisInfections and infestations | 28/121 | 30/120 |
| InfluenzaInfections and infestations | 30/121 | 27/120 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 26/121 | 22/120 |
| NasopharyngitisInfections and infestations | 23/121 | 21/120 |
| Conjunctivitis AllergicEye disorders | 15/121 | 20/120 |
| EczemaSkin and subcutaneous tissue disorders | 11/121 | 16/120 |
| Otitis MediaInfections and infestations | 15/121 | 15/120 |
| Age Continuous(Years) | Budesonide | Conventional Therapy | Total |
|---|---|---|---|
| Mean | 8.9 ± 2.6 | 8.6 ± 2.3 | 8.8 ± 2.5 |
| Sex: Female, Male(Participants) | Budesonide | Conventional Therapy | Total |
|---|---|---|---|
| Female | 36 | 27 | 63 |
| Male | 85 | 93 | 178 |
The record gives a start of Dec 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide